Notably, the disease group known as neurodegeneration with brain iron accumulation (NBIA) refers to neurodegenerative disorders associated with altered iron metabolism in the lesion area and includes Alzheimer’s disease (AD),42 Parkinson’s disease (PD),43 and Huntington’s disease (HD).44 In addition, ablating or inactivating GPX4 promotes neuronal damage and neurodegeneration.6,7 In experimental models of degenerative brain conditions, both ferroptosis inhibitors and iron chelators were shown to improve outcome and prognosis.45–48. This evidence concerns the gene GPX4 and Parkinson disease.